[PDF] Top 20 A controlled trial of natalizumab for relapsing multiple sclerosis.

... among natalizumab-treated patients should be interpreted with caution, since the visual-analogue scale used to assess well-being has not been widely ...the natalizumab-treated pa- tients, the clinical ... See full document

... Approved medications for MS, such as beta interferons or glatiramer acetate have limited therapeutic efficacy or, in the case of natalizumab, mitoxantrone or fingolimod, may be associated with severe side effects. ... See full document

... either to BG-12 at a dose of either 240 mg/twice a day or 240 mg/three times a day or to placebo. Both BG-12 doses were associated with a significant decrease in the proportion of patients who relapsed at 2 years ... See full document

... for relapsing multiple ...in Relapsing–Remitting MS [DEFINE] and Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis [CONFIRM]) demonstrated significant ... See full document

... profile. Natalizumab has been proven in large-scale, blinded, randomized, controlled trials to have good effect on preventing relapses and decreasing the risk of sustained progression of disability in ... See full document

... Abstract: Multiple sclerosis is a frequent neurologic disease, which causes sensory impairment, fatigue, cognitive deficits, imbalance, loss of mobility, spasticity, and bladder and bowel ...disability. ... See full document

... placebo-controlled trial rituximab reduced new MRI gadolinium-enhancing lesions by 91% and the proportion of patients with relapses ...II trial of rituximab in PPMS failed to meet its primary ... See full document

... of natalizumab, considerable progress has been made in identification of risk factors for PML and approaches to risk minimization, and long-term studies to define better when to start or stop treatment and to ... See full document

... in multiple sclerosis ...in relapsing-remitting MS (RRMS) patients receiving an immunosuppressive treatment with natalizumab (NAT), or an immunomodulatory treatment with glatiramer acetate ... See full document

... National Multiple Sclerosis Society, from posters and flyers distributed to neurology clinics in the Iowa City/Cedar Rapids, Iowa corridor area (to include the Iowa City Veterans Affairs Medical Center), ... See full document

... Because natalizumab is second-line therapy at our center, only patients with active and breakthrough disease can receive treatment with ...with natalizumab could possibly show higher normalization of LWM ... See full document

... of relapsing–remitting multiple sclerosis (RRMS) has been proven in two phase III studies: DEFINE (Deter- mination of the Efficacy and Safety of Oral Fumarate in relapsing–remitting ... See full document

... of natalizumab in February 2005, and two PML patients with MS had received combination therapy with natalizumab and intramuscular IFN β ...together, natalizumab has been restricted to use as a ... See full document

... for multiple sclerosis ...of relapsing–remitting MS patients not adequately responding to disease-modifying therapy have been reported to range from 7% to ...49%. Natalizumab and fingolimod ... See full document

... of relapsing multiple ...in relapsing multiple sclerosis, along with sustained long-term beneficial effects, and it is attractive for its once-yearly ... See full document

... III trial has been conducted using ocrelizumab for primary progressive multiple sclerosis ...placebo-controlled trial enrolled PPMS patients (ages 18–55, baseline EDSS ... See full document

... initiating natalizumab at the outpatient neurology clinic of our center were screened according to the indication criteria used at our ...start natalizumab treatment had already been ...continued ... See full document

... Teriflunomide Multiple Sclerosis Oral (TEMSO) trial was the first Phase III clinical trial assessing the efficacy of teriflunomide in MS ...in relapsing MS patients. Enrolled patients ... See full document

... as natalizumab, hereafter called “escalation strategy”) ...to natalizumab, in patients affected by RRMS who have failed first-line treatment with either IFNs or GA [6], adopting the Italian Societal ... See full document

... BRAVO trial is ongoing at the time of this review. This Phase III trial is a multinational, randomized, parallel- group, placebo-controlled study comparing the effect of oral laquinimod ... See full document